Viatris (VTRS) Net Income towards Common Stockholders Growth (1y) (2020 - 2026)
Powered by 
Analysis
Viatris (VTRS) Net Income towards Common Stockholders Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.60 Bn | 38.94 Bn | 2.15 Bn | -304.98% |
| 2 | Viatris | 19.15 Bn | 18.27 Bn | 1.46 Bn | -2,482.61% |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | -71.72% |
| 4 | Amneal Pharmaceuticals | 5.49 Bn | 5.36 Bn | 334.51 Mn | 95.49% |
| 5 | Bausch Health Companies | 2.35 Bn | 516.55 Mn | 2.10 Bn | 103.13% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 203.33% |
| 8 | Amphastar Pharmaceuticals | 996.17 Mn | 706.05 Mn | 93.47 Mn | -2.20% |
| 9 | Fennec Pharmaceuticals | 404.39 Mn | 363.15 Mn | 17.15 Mn | 162.60% |
| 10 | RedHill Biopharma | 176.59 Mn | 176.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,482.61% |
| Mar 31, 2026 | 105.80% |
| Dec 31, 2025 | 34.15% |
| Sep 30, 2025 | -235.23% |
| Jun 30, 2025 | 98.59% |
| Mar 31, 2025 | -2,770.76% |
| Dec 31, 2024 | 32.54% |
| Sep 30, 2024 | -71.41% |
| Jun 30, 2024 | -223.64% |
| Mar 31, 2024 | -49.31% |
| Dec 31, 2023 | -175.71% |
| Sep 30, 2023 | -6.41% |
| Jun 30, 2023 | -15.90% |
| Mar 31, 2023 | -43.71% |
| Dec 31, 2022 | 483.32% |
| Sep 30, 2022 | 13.74% |
| Jun 30, 2022 | 212.43% |
| Mar 31, 2022 | 138.47% |
| Dec 31, 2021 | 71.19% |
| Sep 30, 2021 | 284.32% |